Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies.

D'Souza JW, Reddy S, Goldsmith LE, Shchaveleva I, Marks JD, Litwin S, Robinson MK.

PLoS One. 2014 Nov 11;9(11):e112376. doi: 10.1371/journal.pone.0112376. eCollection 2014.

2.

Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.

Kang JC, Poovassery JS, Bansal P, You S, Manjarres IM, Ober RJ, Ward ES.

MAbs. 2014 Mar-Apr;6(2):340-53. doi: 10.4161/mabs.27658. Epub 2013 Dec 26.

4.

Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.

Zhou Y, Goenaga AL, Harms BD, Zou H, Lou J, Conrad F, Adams GP, Schoeberl B, Nielsen UB, Marks JD.

Mol Cancer Ther. 2012 Jul;11(7):1467-76. doi: 10.1158/1535-7163.MCT-11-1038. Epub 2012 May 7.

5.

A rapid method to regenerate piezoelectric microcantilever sensors (PEMS).

Loo L, Wu W, Shih WY, Shih WH, Borghaei H, Pourrezaei K, Adams GP.

Sensors (Basel). 2011;11(5):5520-8.

6.

Impact of expression system on the function of the C6.5 diabody PET radiotracer.

Miller J, Doss M, McQuillen R, Shaller CC, Tolner B, Yu JQ, Chester K, Robinson MK.

Tumour Biol. 2012 Jun;33(3):617-27. doi: 10.1007/s13277-012-0361-z. Epub 2012 Mar 1.

7.

Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles.

Peng XH, Wang Y, Huang D, Wang Y, Shin HJ, Chen Z, Spewak MB, Mao H, Wang X, Wang Y, Chen ZG, Nie S, Shin DM.

ACS Nano. 2011 Dec 27;5(12):9480-93. doi: 10.1021/nn202410f. Epub 2011 Nov 4.

8.

Highly sensitive detection of HER2 extracellular domain in the serum of breast cancer patients by piezoelectric microcantilevers.

Loo L, Capobianco JA, Wu W, Gao X, Shih WY, Shih WH, Pourrezaei K, Robinson MK, Adams GP.

Anal Chem. 2011 May 1;83(9):3392-7. doi: 10.1021/ac103301r. Epub 2011 Mar 30.

9.

Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment.

Reddy S, Shaller CC, Doss M, Shchaveleva I, Marks JD, Yu JQ, Robinson MK.

Clin Cancer Res. 2011 Mar 15;17(6):1509-20. doi: 10.1158/1078-0432.CCR-10-1654. Epub 2010 Dec 21.

10.

Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging.

Yang L, Mao H, Wang YA, Cao Z, Peng X, Wang X, Duan H, Ni C, Yuan Q, Adams G, Smith MQ, Wood WC, Gao X, Nie S.

Small. 2009 Feb;5(2):235-43. doi: 10.1002/smll.200800714.

11.

Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro.

Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks JD, Adams GP.

Br J Cancer. 2008 Nov 4;99(9):1415-25. doi: 10.1038/sj.bjc.6604700. Epub 2008 Oct 7.

12.

Label-free, all-electrical, in situ human epidermal growth receptor 2 detection.

Capobianco JA, Shih WY, Yuan QA, Adams GP, Shih WH.

Rev Sci Instrum. 2008 Jul;79(7):076101. doi: 10.1063/1.2949831.

13.

Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.

Zhou Y, Drummond DC, Zou H, Hayes ME, Adams GP, Kirpotin DB, Marks JD.

J Mol Biol. 2007 Aug 24;371(4):934-47. Epub 2007 May 10.

Items per page

Supplemental Content

Write to the Help Desk